Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets and dendritic cells in patients with JAK2(V617F) -positive essential thrombocythemia and polycythemia vera

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin Lymphoma and in Hodgkin Lymphoma survivors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The capacity of CD4+ Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Long-term therapy with IFN-α2 is associated with sustained major molecular remissions in JAK2-positive ET and PV. The efficacy of IFN-α2 may be partly mediated by modulation of immune cells, which was investigated in twenty patients with ET (n= 6) and PV (n=14). The frequency of CD4(+) CD25(+) Foxp3(+) T cells was significantly increased during IFN-α2 treatment in all patients (P<0.0001). A significant expansion of the CD56(bright) NK cells (P=0.0002) and a concomitant decrease in the frequency of CD56(dim) NK cells (P<0.0001) was also detected. Myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) were studied in nine patients and decreased frequencies of both cell types were observed during the course of treatment. On both mDCs and pDCs, HLA-ABC expression was upregulated (P=0.003), but decreasing expression levels of HLA-DR was detected on mDCs. The expression of CD40 (P=0.002), CD83 (P=0.03) and CD86 (P=0.01) increased, but was confined to pDCs. Furthermore, PD-L1 expression was reduced on mDC (P=0.003) and increased on pDCs (P=0.02). No significant correlations were found between the changes in immune cells and hematologic or molecular responses achieved in our cohort of patients. So forth, it remains to be revealed whether the profound changes in circulating immune cells contribute to the beneficial effects of long-term IFN-α2 treatment in some patients. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalEuropean Journal of Haematology
Volume97
Issue number1
Pages (from-to)83-92
ISSN0902-4441
DOIs
Publication statusPublished - 19 Sep 2016

ID: 45944165